UT Southwestern Medical Center develops advanced non-viral delivery platforms, including Selective Organ Targeting (SORT) lipid nanoparticles, to enable precise, systemic delivery of genetic medicines like mRNA and CRISPR/Cas gene editors to targeted tissues and cells. The technology facilitates the next generation of genetic therapies for diseases ranging from cancer to genetic disorders, currently supported by research collaborations with industry partners.
UT Southwestern Medical Center is advancing a suite of RNA and gene-editing delivery technologies focused on overcoming the challenges of systemic administration. Through its Program in Genetic Drug Engineering, the center develops sophisticated delivery systems, including Selective Organ Targeting (SORT) lipid nanoparticles (LNPs). These synthetic carriers are engineered to transport genetic payloads—such as mRNA, siRNA, and CRISPR/Cas components—safely and precisely to specific tissues and cell types in vivo, extending therapeutic reach beyond the liver to organs like the lungs and spleen.
The technology centers on the design of non-viral lipid nanoparticles that enhance the stability and intracellular delivery of fragile genetic medicines. Key capabilities and features include:
The technology is currently at TRL 4-5. The underlying platforms, particularly the SORT LNP technology and the ability to perform in vivo CRISPR/Cas editing using synthetic nanoparticles, have been successfully validated through...
UT Southwestern Medical Center is a leading academic medical center within the University of Texas System, combining biomedical research, education, and a major clinical enterprise in Dallas. Co-located hospitals and outpatient networks provide direct access to clinicians, diverse patient populations, and real‑world data, enabling rapid design and execution of clinical studies. Companies engage through on‑campus incubator space, shared core facilities, and collaboration models that range from sponsored research to multi‑site trials. Research is supported primarily by NIH, with additional competitive federal awards from other national agencies. A dedicated technology transfer office streamlines IP protection, licensing, and startup formation to accelerate commercialization.